Etiology of angiogenesis inhibition-related hypertension

Current Opinion in Pharmacology

Volumn 21, Issue , 2015, Pages 7-13

  Lankhorst, Stephanie ^a   Saleh, Langeza ^a   Danser, A H Jan ^a   Van Den Meiracker, Anton H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS INHIBITOR; ENDOTHELIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NITRIC OXIDE; RENIN; VASCULOTROPIN; VASCULOTROPIN RECEPTOR; ENDOTHELIN 1; VASCULOTROPIN A;

ADRENERGIC SYSTEM; BLOOD PRESSURE REGULATION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG SAFETY; ENZYME REPRESSION; HUMAN; HYPERTENSION; INCIDENCE; INTRACELLULAR SIGNALING; KIDNEY INJURY; KIDNEY TUBULE PRESSURE; MOLECULAR PATHOLOGY; NONHUMAN; OUTCOME ASSESSMENT; PROTEIN EXPRESSION; PROTEIN TARGETING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; ANIMAL; CHEMICALLY INDUCED; DRUG EFFECTS; KIDNEY; METABOLISM; PHYSIOLOGY;

ANGIOGENESIS INHIBITORS; ANIMALS; ENDOTHELIN-1; HUMANS; HYPERTENSION; KIDNEY; NITRIC OXIDE; RENIN-ANGIOTENSIN SYSTEM; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84918563926     PISSN: 14714892     EISSN: 14714973     Source Type: Journal    
DOI: 10.1016/j.coph.2014.11.010     Document Type: Review

References (50)

1. S. Lee, T.T. Chen, C.L. Barber, M.C. Jordan, J. Murdock, S. Desai, N. Ferrara, A. Nagy, K.P. Roos, and M.L. Iruela-Arispe Autocrine VEGF signaling is required for vascular homeostasis Cell 130 2007 691 703
2. L.M. Ellis, and D.J. Hicklin VEGF-targeted therapy: mechanisms of anti-tumour activity Nat Rev Cancer 8 2008 579 591
3. N. Ferrara Vascular endothelial growth factor: basic science and clinical progress Endocr Rev 25 2004 581 611
4. M.H.W. Kappers, J.H.M. van Esch, S. Sleijfer, A.H.J. Danser, and A.H. van den Meiracker Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects J Hypertens 27 2009 2297 2309
5. S. Takahashi Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy Biol Pharm Bull 34 2011 1785 1788
6. C.S. Facemire, A.B. Nixon, R. Griffiths, H. Hurwitz, and T.M. Coffman Vascular endothelial growth factor receptor 2 controls blood pressure by regulating nitric oxide synthase expression Hypertension 54 2009 652 658
7. S. Esser, K. Wolburg, H. Wolburg, G. Breier, T. Kurzchalia, and W. Risau Vascular endothelial growth factor induces endothelial fenestrations in vitro J Cell Biol 140 1998 947 959
8. T. Kamba, B.Y. Tam, H. Hashizume, A. Haskell, B. Sennino, M.R. Mancuso, S.M. Norberg, S.M. O'Brien, R.B. Davis, and L.C. Gowen VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart Circ Physiol 290 2006 H560 H576
9. S. Lankhorst, M.H.W. Kappers, J.H.M. van Esch, A.H.J. Danser, and A.H. van den Meiracker Hypertension during vascular endothelial growth factor inhibition: focus on nitric oxide, endothelin-1, and oxidative stress Antioxid Redox Signal 20 2014 135 145
10. S.E. Maynard, J.Y. Min, J. Merchan, K.H. Lim, J. Li, S. Mondal, T.A. Libermann, J.P. Morgan, F.W. Sellke, and I.E. Stillman Excess placental soluble fms-like tyrosine kinase 1 (SFLT1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia J Clin Invest 111 2003 649 658
11. B.I. Rini, B. Escudier, P. Tomczak, A. Kaprin, C. Szczylik, T.E. Hutson, M.D. Michaelson, V.A. Gorbunova, M.E. Gore, and I.G. Rusakov Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): a randomised phase 3 trial Lancet 378 2011 1931 1939
12. O.P. Hamnvik, T.K. Choueiri, A. Turchin, R.R. McKay, L. Goyal, M. Davis, M.D. Kaymakcalan, and J.S. Williams Clinical risk factors for the development of hypertension in patients treated with inhibitors of the VEGF signaling pathway Cancer 2014 [in press]
13. S. Karovic, Y. Wen, T.G. Karrison, G.L. Bakris, M.R. Levine, L.K. House, K. Wu, V. Thomeas, M.A. Rudek, and J.J. Wright Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies Clin Pharmacol Ther 96 2014 27 35
14. M.H.W. Kappers, F.M. Smedts, T. Horn, J.H.M. van Esch, S. Sleijfer, F. Leijten, S. Wesseling, H. Strevens, A.H.J. Danser, and A.H. van den Meiracker The vascular endothelial growth factor receptor inhibitor sunitinib causes a preeclampsia-like syndrome with activation of the endothelin system Hypertension 58 2011 295 302
15. M.L. Maitland, G.L. Bakris, H.R. Black, H.X. Chen, J.B. Durand, W.J. Elliott, S.P. Ivy, C.V. Leier, J. Lindenfeld, and G. Liu Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors J Natl Cancer Inst 102 2010 596 604
16. S.E. Dahlberg, A.B. Sandler, J.R. Brahmer, J.H. Schiller, and D.H. Johnson Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599 J Clin Oncol 28 2010 949 954
17. B.I. Rini, D.P. Cohen, D.R. Lu, I. Chen, S. Hariharan, M.E. Gore, R.A. Figlin, M.S. Baum, and R.J. Motzer Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 763 773
18. L. Horsley, K. Marti, and G.C. Jayson Is the toxicity of anti-angiogenic drugs predictive of outcome? A review of hypertension and proteinuria as biomarkers of response to anti-angiogenic therapy Expert Opin Drug Metab Toxicol 8 2012 283 293
19. A. Bouloumie, V.B. Schini-Kerth, and R. Busse Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells Cardiovasc Res 41 1999 773 780
20. J.D. Hood, C.J. Meininger, M. Ziche, and H.J. Granger VEGF upregulates ecnos message, protein, and no production in human endothelial cells Am J Physiol 274 1998 H1054 H1058
21. J. Kroll, and J. Waltenberger VEGF-A induces expression of enos and inos in endothelial cells via VEGF receptor-2 (KDR) Biochem Biophys Res Commun 252 1998 743 746
22. B.Q. Shen, D.Y. Lee, and T.F. Zioncheck Vascular endothelial growth factor governs endothelial nitric-oxide synthase expression via a KDR/Flk-1 receptor and a protein kinase c signaling pathway J Biol Chem 274 1999 33057 33063
23. A.M. Thijs, C.M. van Herpen, F.C. Sweep, A. Geurts-Moespot, P. Smits, W.T. van der Graaf, and G.A. Rongen Role of endogenous vascular endothelial growth factor in endothelium-dependent vasodilation in humans Hypertension 61 2013 1060 1065
24. E.L. Mayer, S.M. Dallabrida, M.A. Rupnick, W.M. Redline, K. Hannagan, N.S. Ismail, H.J. Burstein, and J.A. Beckman Contrary effects of the receptor tyrosine kinase inhibitor vandetanib on constitutive and flow-stimulated nitric oxide elaboration in humans Hypertension 58 2011 85 92
25. K. Eechoute, A.A. van der Veldt, S. Oosting, M.H.W. Kappers, J.A. Wessels, H. Gelderblom, H.J. Guchelaar, A.K. Reyners, C.M. van Herpen, and J.B. Haanen Polymorphisms in endothelial nitric oxide synthase (ENOS) and vascular endothelial growth factor (VEGF) predict sunitinib-induced hypertension Clin Pharmacol Ther 92 2012 503 510
26. N. Steeghs, H. Gelderblom, J.O. Roodt, O. Christensen, P. Rajagopalan, M. Hovens, H. Putter, T.J. Rabelink, and E. de Koning Hypertension and rarefaction during treatment with telatinib, a small molecule angiogenesis inhibitor Clin Cancer Res 14 2008 3470 3476
27. M.H.W. Kappers, J.H.M. van Esch, W. Sluiter, S. Sleijfer, A.H.J. Danser, and A.H. van den Meiracker Hypertension induced by the tyrosine kinase inhibitor sunitinib is associated with increased circulating endothelin-1 levels Hypertension 56 2010 675 681
28. P. Kruzliak, G. Kovacova, and O. Pechanova Therapeutic potential of nitric oxide donors in the prevention and treatment of angiogenesis-inhibitor-induced hypertension Angiogenesis 16 2013 289 295
29. S. Lankhorst, M.H.W. Kappers, J.H.M. van Esch, F.M. Smedts, S. Sleijfer, R.H. Mathijssen, H.J. Baelde, A.H.J. Danser, and A.H. van den Meiracker Treatment of hypertension and renal injury induced by the angiogenesis inhibitor sunitinib: preclinical study Hypertension 64 2014 1282 1289
30. A. Matsuura, W. Yamochi, K. Hirata, S. Kawashima, and M. Yokoyama Stimulatory interaction between vascular endothelial growth factor and endothelin-1 on each gene expression Hypertension 32 1998 89 95
31. K.J. Lee, M.K. Kim, Y.H. Park, H.J. Seol, J.E. Lim, J.N. Lee, and M.J. Oh Vascular endothelial growth factor induces endothelin-1 production via matrix metalloproteinase-2 rather than endothelin-converting enzyme-1 Hypertens Pregnancy 26 2007 189 199
32. G.P. Star, M. Giovinazzo, E. Lamoureux, and D. Langleben Effects of vascular endothelial growth factor on endothelin-1 production by human lung microvascular endothelial cells in vitro Life Sci 2014 [in press]
33. N. Dhaun, and D.J. Webb Receptor tyrosine kinase inhibition, hypertension, and proteinuria: is endothelin the smoking gun? Hypertension 56 2010 575 577
34. F. Li, J.R. Hagaman, H.S. Kim, N. Maeda, J.C. Jennette, J.E. Faber, S.A. Karumanchi, O. Smithies, and N. Takahashi eNOS deficiency acts through endothelin to aggravate sFlt-1-induced pre-eclampsia-like phenotype J Am Soc Nephrol 23 2012 652 660
35. F. Amraoui, L. Spijkers, H. Hassani Lahsinoui, L. Vogt, J. van der Post, S. Peters, G. Afink, C. Ris-Stalpers, and B.J. van den Born SFlt-1 elevates blood pressure by augmenting endothelin-1-mediated vasoconstriction in mice PLOS ONE 9 2014 e91897
36. P.N. Banfor, P.A. Franklin, J.A. Segreti, D.L. Widomski, S.K. Davidsen, D.H. Albert, B.F. Cox, R.M. Fryer, and G.A. Gintant ETA receptor blockade with atrasentan prevents hypertension with the multitargeted tyrosine kinase inhibitor ABT-869 in telemetry-instrumented rats J Cardiovasc Pharmacol 53 2009 173 178
37. M.H.W. Kappers, V.J. de Beer, Z. Zhou, A.H.J. Danser, S. Sleijfer, D.J. Duncker, A.H. van den Meiracker, and D. Merkus Sunitinib-induced systemic vasoconstriction in swine is endothelin mediated and does not involve nitric oxide or oxidative stress Hypertension 59 2012 151 157
38. A.A. van der Veldt, M.P. de Boer, E. Boven, E.C. Eringa, A.J. van den Eertwegh, V.W. van Hinsbergh, Y.M. Smulders, and E.H. Serne Reduction in skin microvascular density and changes in vessel morphology in patients treated with sunitinib Anticancer Drugs 21 2010 439 446
39. J.J. Mourad, G. des Guetz, H. Debbabi, and B.I. Levy Blood pressure rise following angiogenesis inhibition by, bevacizumab. A crucial role for, microcirculation Ann Oncol 19 2008 927 934
40. M.P. de Boer, A.A. van der Veldt, N.A. Lankheet, N.J. Wijnstok, A.J. van den Eertwegh, E. Boven, and E.H. Serne Sunitinib-induced reduction in skin microvascular density is a reversible phenomenon Ann Oncol 21 2010 1923 1924
41. J.T. Belcik, Y. Qi, B.A. Kaufmann, A. Xie, S. Bullens, T.K. Morgan, S.P. Bagby, G. Kolumam, J. Kowalski, and J.A. Oyer Cardiovascular and systemic microvascular effects of anti-vascular endothelial growth factor therapy for cancer J Am Coll Cardiol 60 2012 618 625
42. A.H. van den Meiracker, A.H.J. Danser, S. Sleijfer, and M.H.W. Kappers Re: Hypertension as a biomarker of efficacy in patients with metastatic renal cell carcinoma treated with sunitinib J Natl Cancer Inst 103 2011 1557 [author reply 1558]
43. A.S. Greene, P.J. Tonellato, J. Lui, J.H. Lombard, and A.W. Cowley Jr. Microvascular rarefaction and tissue vascular resistance in hypertension Am J Physiol 256 1989 H126 H131
44. J.W. Gu, R.D. Manning Jr., E. Young, M. Shparago, B. Sartin, and A.P. Bailey Vascular endothelial growth factor receptor inhibitor enhances dietary salt-induced hypertension in Sprague-Dawley rats Am J Physiol Regul Integr Comp Physiol 297 2009 R142 R148
45. J.P. Granger Vascular endothelial growth factor inhibitors and hypertension: a central role for the kidney and endothelial factors? Hypertension 54 2009 465 467
46. A. Machnik, W. Neuhofer, J. Jantsch, A. Dahlmann, T. Tammela, K. Machura, J.K. Park, F.X. Beck, D.N. Muller, and W. Derer Macrophages regulate salt-dependent volume and blood pressure by a vascular endothelial growth factor-c-dependent buffering mechanism Nat Med 15 2009 545 552
47. M.L. Veronese, A. Mosenkis, K.T. Flaherty, M. Gallagher, J.P. Stevenson, R.R. Townsend, and P.J. O'Dwyer Mechanisms of hypertension associated with bay 43-9006 J Clin Oncol 24 2006 1363 1369
48. J.O. Curwen, H.L. Musgrove, J. Kendrew, G.H. Richmond, D.J. Ogilvie, and S.R. Wedge Inhibition of vascular endothelial growth factor-a signaling induces hypertension: examining the effect of cediranib (recentin; AZD2171) treatment on blood pressure in rat and the use of concomitant antihypertensive therapy Clin Cancer Res 14 2008 3124 3131
49. M. Skinner, K. Philp, D. Lengel, L. Coverley, E. Lamm Bergstrom, P. Glaves, H. Musgrove, H. Prior, M. Braddock, and R. Huby The contribution of VEGF signalling to fostamatinib-induced blood pressure elevation Br J Pharmacol 171 2014 2308 2320
50. C. Gennari-Moser, E.V. Khankin, G. Escher, F. Burkhard, B.M. Frey, S.A. Karumanchi, F.J. Frey, and M.G. Mohaupt Vascular endothelial growth factor-a and aldosterone: relevance to normal pregnancy and preeclampsia Hypertension 61 2013 1111 1117